A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Gorriti, Buenos Aires 5737, Argentina
Kashiwa-shi, Chiba 2778577, Japan
Kurume-shi, Fukuoka 8300011, Japan
Nishinomiya-shi, Hyōgo 6638501, Japan
Suita-shi, Osaka 565-0871, Japan
Bunkyo-ku, Tokyo 1138655, Japan
Chuo-ku, Tokyo 1040045, Japan
Mitaka-shi, Tokyo 181-8611, Japan
Musashino-shi, Tokyo 1808610, Japan
Shinjuku-ku, Tokyo 162-8655, Japan
Leningrad Region, 188663, Russia
Gyeongsangnam-do, 50612, South Korea
Jeollanam-do, 58128, South Korea
Yunlin, 632, Taiwan